Cardlytics, Inc (CDLX) Key Metrics
CDLX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $12.0M
- Enterprise value
- $182.4M
- P/E (TTM)
- —
- Forward P/E
- 36.5
- PEG ratio
- —
- Price / sales
- 0.1 10-yr median 1.2
- Price / book
- 2.1 10-yr median 3.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.71
CDLX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCDLX valuation Price multiples at each fiscal year-end price.
CDLX returns How much profit the business earns on the capital it uses.
CDLX per-share figures Results divided by the shares outstanding at year-end.
CDLX financial health Debt, liquidity and how easily interest is covered.
CDLX efficiency & capital use Working capital cycle and where the cash goes.
CDLX valuation history
CDLX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CDLX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CDLX cash returned to shareholders
CDLX price vs earnings per share
CDLX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $61.1M | $179.4M | $336.1M | $193.2M | $2.13B | $3.89B | $1.49B | $206.4M | — | — |
| Enterprise value | $227.7M | $335.5M | $510.3M | $306.5M | $2.09B | $3.78B | $1.39B | $213.5M | — | — |
| Price / sales | 0.3 | 0.6 | 1.1 | 0.6 | 8.0 | 20.8 | 7.1 | 1.4 | — | — |
| Price / book | — | 2.6 | 2.5 | 0.9 | 3.1 | 24.7 | 10.4 | 4.0 | — | — |
| Price / operating cash flow | 6.6 | — | — | — | — | — | 130.3 | — | — | — |
| EV / sales | 1.0 | 1.2 | 1.7 | 1.0 | 7.8 | 20.2 | 6.6 | 1.4 | — | — |
| Earnings yield | −169.4% | −105.5% | −40.1% | −240.9% | −6.0% | −1.4% | −1.1% | −25.7% | — | — |
| Free cash flow yield | −10.6% | −15.7% | −3.7% | −34.9% | −2.4% | −0.5% | 0.0% | −12.8% | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | 0.0% | 20.7% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $11.50 | $37.10 | $92.10 | $57.80 | $660.90 | $1,427.70 | $628.60 | $108.30 | — | — |
| Per share | ||||||||||
| Revenue per share | $43.92 | $57.55 | $84.74 | $89.33 | $82.95 | $68.68 | $88.62 | $79.06 | $6.68 | $8.04 |
| Earnings per share | −$19.48 | −$39.14 | −$36.92 | −$139.22 | −$39.92 | −$20.37 | −$7.22 | −$27.83 | −$1.01 | −$5.40 |
| Operating cash flow per share | $1.75 | −$1.82 | −$0.05 | −$16.13 | −$11.96 | −$2.79 | $4.82 | −$9.97 | −$1.13 | −$2.32 |
| Free cash flow per share | −$1.22 | −$5.82 | −$3.45 | −$20.17 | −$15.86 | −$6.51 | $0.18 | −$13.82 | −$1.22 | −$2.50 |
| Cash per share | $9.17 | $13.56 | $25.17 | $36.48 | $72.50 | $107.76 | $43.99 | $20.79 | $1.09 | $1.63 |
| Book value per share | −$1.23 | $14.47 | $36.94 | $63.32 | $214.49 | $57.76 | $60.33 | $27.27 | −$10.69 | −$15.46 |
| Tangible book value per share | −$23.04 | −$20.84 | −$55.37 | −$64.19 | −$59.16 | $55.28 | $58.56 | $26.22 | −$10.74 | −$15.49 |
| Capex per share | $2.97 | $3.99 | $3.40 | $4.04 | $3.90 | $3.72 | $4.64 | $3.85 | $0.08 | $0.18 |
| Debt per share | $40.54 | $45.83 | $72.93 | $70.40 | $61.25 | $69.13 | $0.02 | $24.51 | $3.44 | $8.13 |
| Shares outstanding | 5.3M | 4.8M | 3.6M | 3.3M | 3.2M | 2.7M | 2.4M | 1.9M | 19.5M | 14.0M |
| Change in shares outstanding | +9.8% | +32.5% | +9.2% | +3.8% | +18.3% | +14.6% | +24.6% | −90.2% | +39.2% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −184.9% | −77.8% | −103.1% | −30.3% | −36.9% | −17.6% | — | — | — |
| Return on invested capital (ROIC) | −19.3% | −57.7% | −33.8% | −73.8% | −27.4% | −93.7% | −28.0% | — | — | — |
| Return on assets (ROA) | −30.5% | −39.2% | −21.3% | −47.6% | −15.2% | −17.1% | −9.1% | −41.7% | −20.9% | −89.5% |
| Return on tangible assets | −61.0% | −85.3% | −56.8% | −175.5% | −33.6% | −13.3% | −7.8% | −34.9% | −19.7% | −87.6% |
| Free cash flow margin | −2.8% | −10.1% | −4.1% | −22.6% | −19.1% | −9.5% | 0.2% | −17.5% | −18.2% | −31.1% |
| Financial health | ||||||||||
| Total debt | $215.3M | $221.7M | $266.1M | $235.3M | $197.2M | $188.1M | $37,000 | $46.7M | $67.2M | $114.1M |
| Cash & short-term investments | $48.7M | $65.6M | $91.8M | $121.9M | $233.5M | $293.2M | $104.5M | $39.6M | $21.3M | $22.8M |
| Net debt | $166.6M | $156.1M | $174.3M | $113.4M | −$36.2M | −$105.1M | −$104.4M | $7.1M | $46.0M | $91.3M |
| Debt / equity | — | 3.17 | 1.97 | 1.11 | 0.29 | 1.20 | 0.00 | 0.90 | — | — |
| Debt / assets | 0.75 | 0.56 | 0.46 | 0.34 | 0.16 | 0.45 | 0.00 | 0.30 | 0.67 | 1.31 |
| Current ratio | 1.75 | 1.19 | 1.31 | 1.00 | 1.10 | 4.74 | 2.50 | 2.40 | 1.77 | 1.73 |
| Quick ratio | 1.75 | 1.19 | 1.31 | 1.00 | 1.10 | 4.74 | 2.49 | 2.01 | 1.77 | 1.72 |
| Interest coverage | -4.4 | -22.0 | -21.9 | -114.6 | -9.5 | -15.5 | -12.6 | -12.5 | -2.1 | -9.1 |
| Working capital | $58.9M | $29.0M | $52.8M | $1.1M | $31.4M | $304.3M | $117.3M | $72.4M | $32.5M | $28.7M |
| Invested capital | $160.1M | $226.1M | $309.1M | $325.0M | $654.5M | $52.1M | $38.8M | $59.1M | −$162.7M | −$125.6M |
| Tangible asset value | −$122.4M | −$100.8M | −$202.1M | −$214.5M | −$190.5M | $150.4M | $139.1M | $50.0M | −$209.6M | −$217.3M |
| Net current asset value | −$154.9M | −$144.7M | −$215.4M | −$229.6M | −$214.4M | $120.2M | $114.7M | $22.6M | −$234.8M | −$235.4M |
| Graham net-net per share | −$33.79 | −$36.57 | −$69.34 | −$80.08 | −$78.16 | $34.13 | $36.85 | −$3.48 | −$12.79 | −$17.68 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | $0 | $0 | $40.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | 0.0% | — | — | — |
| Capex / revenue | 6.8% | 6.9% | 4.0% | 4.5% | 4.7% | 5.4% | 5.2% | 4.9% | 1.3% | 2.3% |
| Capex / operating cash flow | 169.9% | — | — | — | — | — | 96.2% | — | — | — |
| Capex / depreciation | 0.58 | 0.69 | 0.42 | 0.31 | 0.35 | 0.87 | 2.43 | 2.24 | 0.54 | 0.60 |
| Stock-based compensation / revenue | 12.1% | 14.5% | 13.3% | 15.0% | 18.8% | 17.3% | 7.5% | 17.8% | 3.9% | 3.1% |
| R&D / revenue | 17.0% | 17.8% | 16.6% | 18.2% | 14.3% | 9.4% | 5.6% | 10.8% | 9.3% | 12.3% |
| SG&A / revenue | 37.2% | 39.2% | 37.6% | 52.3% | 49.5% | 49.1% | 38.3% | 50.5% | 39.9% | 46.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 150.5 | 152.8 | 145.2 | 145.0 | 139.2 | 167.9 | 126.5 | 135.4 | 133.1 | 134.2 |
| Days of inventory on hand | — | — | — | 0.2 | 0.2 | 0.4 | 28.4 | 77.0 | — | 1.0 |
| Days payables outstanding | 10.0 | 9.4 | 8.4 | 8.2 | 6.7 | 3.8 | 4.6 | 6.9 | 8.9 | 17.0 |
| Cash conversion cycle (days) | 140.4 | 143.4 | 136.9 | 137.0 | 132.8 | 164.4 | 150.3 | 205.4 | 124.2 | 118.2 |
| Receivables turnover | 2.43 | 2.39 | 2.51 | 2.52 | 2.62 | 2.17 | 2.88 | 2.70 | 2.74 | 2.72 |
| Payables turnover | 36.37 | 38.80 | 43.67 | 44.35 | 54.76 | 95.38 | 78.71 | 52.56 | 40.92 | 21.47 |
| Inventory turnover | — | — | — | 2,124.69 | 1,597.81 | 1,034.46 | 12.86 | 4.74 | — | 348.13 |
| Asset turnover | 0.69 | 0.58 | 0.49 | 0.31 | 0.32 | 0.58 | 1.11 | 1.18 | 1.39 | 1.33 |
| Average receivables | $96.2M | $116.5M | $123.0M | $118.6M | $101.9M | $86.0M | $73.0M | $55.9M | $47.5M | $41.5M |
| Average payables | $3.5M | $4.1M | $4.1M | $4.2M | $3.0M | $1.3M | $1.7M | $1.8M | $2.0M | $3.4M |
| Average inventory | — | — | — | $87,500 | $102,500 | $119,500 | $10.2M | $20.2M | — | $208,000 |
| Intangibles / total assets | 40.6% | 43.5% | 58.7% | 61.6% | 69.7% | 1.6% | 1.9% | 1.3% | 1.0% | 0.5% |
Computed from CDLX's annual financial statements (latest annual report filed March 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CDLX valuation and financial ratios
Cardlytics earned a return on invested capital of −19.3% in fiscal 2025. It ended the year with $215.3 million of debt and $48.7 million in cash and short-term investments, net debt of $166.6 million. The share count fell 62.1% from 14.0M to 5.3M over 9 years.
See the CDLX income statement, the CDLX chart for price history, or the CDLX stock overview for the latest quote and news.
CDLX key metrics FAQ
What is Cardlytics's ROIC?
Cardlytics's return on invested capital was −19.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Cardlytics have?
Cardlytics had total debt of $215.3 million at the end of fiscal 2025.
What is Cardlytics's free cash flow yield?
Cardlytics generated -$6.5 million of free cash flow in fiscal 2025, a free cash flow yield of −10.6% on its market value at year-end ($61.1 million).
What is Cardlytics's current ratio?
Cardlytics's current ratio was 1.75 at the end of fiscal 2025: current assets were 1.75 times current liabilities.